ArticleClinical and molecular hepatology2026

ERBB3 blockade sensitizes hepatocellular carcinoma to regorafenib after first-line tyrosine kinase inhibitor resistance by inhibiting HIF1A-ABCB1 signaling.

Baorui Tao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.